CLINPROT systemを用いた多発性硬化症におけるCSFプロテオミクス

• 小森 美華

  京都大学大学院医学研究科　臨床神経学

• 松山 由美子

  ブルカーダルトニクス

• 韮澤 崇

  ブルカーダルトニクス

• 田中 正美

  宇多野病院

• 冨本 秀和

  京都大学大学院医学研究科　臨床神経学

• 高橋 良輔

  京都大学大学院医学研究科　臨床神経学

• 田代 啓

  京都府立医科大学　ゲノム医科学

• 近藤 誉之

  長崎神経医療センター

• 池川 雅哉

  京都府立医科大学　ゲノム医科学

書誌事項

タイトル別名

• Cerebrospoinal fluid proteomics in multiple sclerosis by CLINPROT system

抄録

Recent advances in the proteomic technology in search of biomarker or biomarker signature that accurately identifies the clinical syndrome would allow for improved diagnosis and disease monitoring. Diagnosing Multiple Sclerosis(MS) and other demyelinating diseases such as neuromyelitis optica (NMO) is not always easy clinically and the pathogenesis of the two demyelinating diseases remains mystery. Here we adopted CLINPROT system, a magnetic bead-based purification followed by MALDI-TOF MS to profile human cerebrospinal fluids proteins and peptides. CSF samples from patients with definite MS (remission and relapse), NMO (remission and relapse) and primary progressive multiple sclerosis (PPMS) were analyzed. We used a reagent set of chemically coated magnetic beads, reversed phase ClinProtTM and a- cyano-4-hydroxycinnamic acid as the matrix solution. The eluted samples were then dropped onto a MALDI sample plate (AnchorchipTM), and spectra were obtained by an Autoflex II and a subsequent tandem MS analysis was performed by Ultraflex (Bruker Daltonics). The criteria for peak detection were: signal-to-noise ratio >5, 2-Da peak-width filter. The pretreated data were graphed as spectra and evaluated by statistical analysis using the ClinProToolsTM software (Bruker Daltonics).Reproducible profiles were obtained as clear signals and approximately fifty peaks were detected from each of CSF samples. A differential distribution of samples from MS and NMO both in remission was noticeable, while samples from PPMS were not separated effectively using the same platform. One of the key variables contributing to the classification of the samples with an m/z of 3,511 was defined as c-terminal fragment (182-212) of neuroendocrine peptide 7B2 by the tandem MS analysis. The application of CLINPROT system for CSF samples holds the potential to advance our understanding of the biochemical basis of MS and NMO.

収録刊行物

• 日本プロテオーム学会大会要旨集

  日本プロテオーム学会大会要旨集 2008 (0), 93-93, 2008

  日本プロテオーム学会（日本ヒトプロテオーム機構）

キーワード

• CSF
• CLINPROT system
• Multiple Sclerosis

詳細情報

• CRID: 1390282680617293568
• NII論文ID: 130007000304
• DOI: 10.14889/jhupo.2008.0.93.0
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可